Avid Bioservices Inc (CDMO)

[pphmtoolong]

Not so fast, Very.

Hope is high for SUNRISE because of bavituximab's statistically significant improvement in median overall survival delivered in a midstage study. Although its phase 2 trial wasn't without theatrics -- a third-party lab created a problem with the results, requiring Peregrine to restate its survival data -- bavituximab did deliver an overall survival of 11.7 months compared to 7.3 months for the placebo group.

We will soon, very soon, see whether Sunrise delivers the goods or not. Not years, weeks at most months.

GLTA, Especially Bavi-arm Sunrise Patients,

Paul